EGFR and cancer: Given that some immunotherapies (e.g., CD20-, EGFR-, IL-1β- or PCSK9-targeting antibodies) were shown to protect from both cancer and atherosclerosis, inflammatory processes and immunity underlying carcinogenesis and atherogenesis may be closely interconnected.